Bristol-Myers Squibb: receives EU approval for Sprycel
(CercleFinance.com) - US drugmaker Bristol-Myers Squibb said that the European Commission has approved its leukemia drug Sprycel for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
In a a Phase 2 trial, the combination of Sprycel and chemotherapy showed an overall survival rate of 91.5%, the company said.
Sprycel is currently approved in over 60 countries for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
In a a Phase 2 trial, the combination of Sprycel and chemotherapy showed an overall survival rate of 91.5%, the company said.
Sprycel is currently approved in over 60 countries for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Copyright (c) 2019 CercleFinance.com. All rights reserved.